CCA Gives Tips for Transitioning into Adulthood with a Craniofacial Difference
source: pixabay.com

CCA Gives Tips for Transitioning into Adulthood with a Craniofacial Difference

Children's Craniofacial Association (CCA) has posted tips for transitioning to adulthood for those with craniofacial differences. We've summarized some of their recommendations, but you can read the full article here.…

Continue Reading CCA Gives Tips for Transitioning into Adulthood with a Craniofacial Difference

CureVac Joins the Race to Develop a Vaccine Against COVID-19 With Its Successful Phase 1 Trial

According to an article in Biospace, CureVac of Boston, MA, with headquarters in Tübingen, Germany, just announced interim results from its Phase 1 study evaluating CVnCoV, a vaccine candidate against…

Continue Reading CureVac Joins the Race to Develop a Vaccine Against COVID-19 With Its Successful Phase 1 Trial

CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis

CymaBay Therapeutics, a biopharmaceutical company based in Newark, CA, develops and provides access to novel therapies with a recent focus on primary biliary cholangitis (PBC). The company is currently developing…

Continue Reading CymaBay Therapeutics Announces Results of Global Phase 3 ENHANCE Study for Primary Biliary Cholangitis
AMO-02, a Congenital Myotonic Dystrophy Treatment, Granted Rare Pediatric Disease Designation
qimono / Pixabay

AMO-02, a Congenital Myotonic Dystrophy Treatment, Granted Rare Pediatric Disease Designation

The FDA has recently granted the Rare Pediatric Disease (RPD) designation to AMO-02, a treatment for congenital myotonic dystrophy. As there is currently an unmet medical need for this condition,…

Continue Reading AMO-02, a Congenital Myotonic Dystrophy Treatment, Granted Rare Pediatric Disease Designation